How may alcohol affect the efficacy and liver-related risks of etranacogene dezaparvovec (Hemgenix)?

Alcohol may reduce the efficacy of etranacogene dezaparvovec (Hemgenix) and increase the risk of more serious hepatic reactions, particularly during the first year after administration; experience with hepatotoxic substances is limited, and safety and efficacy in these circumstances have not been established.